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Abstract
Background: The efficacy of a highly tailored digital intervention to support medication adherence and feasibility to support
clinical effectiveness as an adjunct to the primary care setting has not been evaluated.
Objective: This trial aimed to assess the behavioral efficacy of a highly tailored digital intervention to support medication
adherence and to evaluate the feasibility of its clinical effectiveness, in patients with either or both hypertension and type 2
diabetes. We also examined quality of life and mechanisms of behavior change. Intervention fidelity, engagement, and satisfaction
were also explored.
Methods: This was a multicenter, individually randomized controlled trial of 2 parallel groups: an intervention group that
received a highly tailored text message and interactive voice response intervention for 12 weeks, and a control group that received
usual care. Medication adherence was measured using self-reports and assessor-blinded practice records of a repeat prescription.
Systolic blood pressure and glucose levels were assessed by nurses blinded to group allocation during practice visits at 3 months
follow-up. Questionnaires obtained data to assess intervention mechanisms of action and satisfaction and digital log files captured
data to evaluate fidelity and engagement.
Results: A total of 135 nonadherent patients (62/135, 46% female; 122/135, 90.3%; aged above 50 years) were randomly
allocated in the intervention (n=79) or in the control group (n=56); of whom 13% (18/135) were lost at follow-up. Medication
adherence was significantly improved in the intervention group compared with the control group (t116=2.27; P=.02, 2-tailed).
Systolic blood pressure was 0.6 mmHg (95% CI −7.423 to 6.301), and hemoglobin A1c was 4.5 mmol/mol (95% CI −13.099 to
4.710) lower in the intervention group compared with the control group. Changes in intentional nonadherence and nonintentional
nonadherence explained the improvements in medication adherence in the intervention group (beta=.074, SE=0.464; P=.04), but
not in the control group (beta=.00, SE 1.35; P=.37). The intervention had 100% fidelity, a median of 12 days of engagement, and
76% overall satisfaction.
Conclusions: Our trial is the first that has been conducted in the United Kingdom and showed that among nonadherent patients
with either or both hypertension and type 2 diabetes, a highly tailored digital intervention was effective at improving treatment
adherence and feasible to obtain clinically meaningful outcomes. Changes in intentional and nonintentional nonadherence predicted
the improvements in medication adherence. The intervention had high fidelity, engagement, and satisfaction. Future research
using a rigorous design is needed to evaluate the clinical effectiveness and cost-effectiveness of the intervention in primary care.
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Introduction
Background
The clinical management of cardio-metabolic conditions, like
hypertension and type 2 diabetes mellitus, is one of the most
common consultations in primary care [1,2] and
pharmacotherapy is an essential part of effective management
of these conditions [3]. However, many patients do not adhere
to their prescribed medication regimen [4], leading to reduced
treatment efficacy, increased risk of complications, additional
consultations, and hospital admissions [5,6]. Medication
adherence can significantly reduce these risks and prevent health
complications [7,8]. It could also result in health care savings,
with estimates from the United Kingdom of approximately US
$115.4 million preventable cost being spent annually, due to
only nonadherence to antihypertensive medications [9].
Setting
Primary health care providers can facilitate treatment adherence,
but their time is limited and expensive. Given the growing
prevalence of hypertension, the associated comorbidities, and
the aging population, it is likely that there will be an increased
need for health care resources to support medication adherence.
Digital interventions are promising strategies to support
adherence [10,11] and can be highly tailored and acceptable
adjunct to primary care consultations [12]. Telephone-based
interventions that deliver text and voice messages may have a
wider reach as they can be delivered to any device, even in
places of low network coverage, and are accessible to people
from all socioeconomic backgrounds and age groups. We have
therefore developed the Medication Adherence for Patient’s
Support intervention, a behavioral intervention that uses text
and voice messages, to support medication adherence in patients
with either or both hypertension and type 2 diabetes as an
adjunct to primary care consultations.
Aims and Objectives
This study aimed to assess if patients with either or both
hypertension and type 2 diabetes, who used the intervention for
3 months in addition to usual care, had improved medication
adherence and if they differed in terms of systolic blood pressure
or hemoglobin A1c, and quality of life at 3 months follow-up.
We have also assessed intervention mechanisms of action, as
well as intervention fidelity, engagement and satisfaction.
However, this feasibility trial primarily aimed to attain evidence
about the feasibility of obtaining medication-related clinical
outcomes to inform a larger effectiveness and cost-effectiveness
trial in primary care.
Methods
Study Design
We used an individually randomized controlled trial of unequal
3:2 allocation ratio with a 3-month follow-up. We used unequal
allocation ratio to increase the information obtained about the
intervention. Intervention group patients received highly tailored
and interactive text and voice recognition messages for 12
weeks, as an adjunct to usual care. The control group received
usual care only [13].
Study Setting
Participants were recruited over 7 months, from March to
September 2018, from 8 primary care practices in the East of
England. We selected a wide range of primary care practices
from different areas of deprivation (based on Index of Multiple
Deprivation), and at least 50% in highly deprived areas, to obtain
information about the reach and implementation of the
intervention in different sites, and to increase the scalability of
the intervention to a larger trial. Follow-up data collection was
conducted between May 2018 and February 2019.
Participant Recruitment and Eligibility Criteria
A member of the practice staff screened medical databases
against the inclusion criteria to identify eligible patients. Patients
were eligible when they met all the following criteria: (1) were
18 years or older, (2) had a diagnosis of hypertension, type 2
diabetes mellitus, or both health conditions; (3) had been
prescribed at least 1 antihypertensive medication or glucose
lowering medication as documented in practice records for a
period of 3 to 6 months before recruitment; and (4) had either
or both poorly controlled blood pressure (controlled by age
group) and glucose levels as logged in their medical records,
or had gaps in collecting repeat prescriptions during the 6
months before the study invitation. When possible, patients’
digital literacy was screened for inclusion.
A general practitioner screened the generated list of potentially
eligible patients against the exclusion criteria to confirm
eligibility. Patients were excluded when they met any of the
following criteria: (1) were taking part in another medication
adherence or digital intervention or (2) had a health condition
that could impair their participation in the study.
Eligible patients were invited to the study by the primary care
practices using text messages, postal invitations, and follow-up
calls to postage invitations, or were recruited opportunistically
during usual care consultations (eg, blood pressure checks and
medication reviews) by health care providers.
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Study Procedures
Interested patients were invited and attended baseline
consultations with a health care provider (a practice nurse or a
health care facilitator), where they were screened for eligibility
(eg, digital literacy) and asked to provide informed consent.
Baseline consultations involved the completion of a baseline
questionnaire, measuring medication adherence, quality of life,
and theoretical determinants associated with intentional
nonadherence and nonintentional nonadherence (eg, necessity
beliefs about medication taking and self-efficacy) and were
facilitated by the health care provider. Responses to the baseline
questionnaire were included in a webpage (which consisted of
the tailoring algorithm, the intervention schedule, the
intervention messages, and the inbound calls) to further inform
the tailored intervention to those allocated to receive the digital
intervention.
After the end of the consultations, patients were randomized to
intervention or control groups and were sent a text message or
a letter with information about which group they are allocated
in. Further, intervention group patients completed information
(on a webpage or verbally during phone calls; depending on
their digital literacy) about their preferred times and frequency
to receive the intervention messages. They were also provided
with more information on how to use the digital delivery modes.
All patients were provided with additional information about
the trial procedures. Baseline consultation was conducted few
days before each patient’s repeat prescription was due for
collection.
Intervention
Intervention group patients received highly tailored and
interactive text and voice recognition messages for 12 weeks,
initiated the day their repeat prescription was due for collection.
The intervention development was guided by the theoretical
framework that distinguishes between intentional and
nonintentional nonadherence [14], previous evidence [11,12,15],
and included behavior change techniques and strategies mapped
onto either or both intentional and nonintentional nonadherence.
Nonintentional nonadherence refers to patients not taking their
medications as prescribed because they forget or misunderstand
the recommendations. Intentional nonadherence refers to patients
not taking their medications as prescribed because they decide
to take less medication or miss a dose or a day of their
medications. The intervention aimed to improve medication
adherence by employing behavior change strategies to modify
either or both intentional and nonintentional nonadherence.
The interactive element of the intervention was utilized for
dynamic tailoring: patients could record a personalized
implementation intention plan to further tailor intervention
content and be grouped to receive more habit formation or
self-monitoring advice based on records and responses obtained
during the intervention. We have also adopted a flexible
approach to intervention delivery, providing participants with
functions to change delivery options (eg, decrease or increase
the frequency of messages or stop the messages). Details of the
intervention development are published elsewhere [12].
Outcomes
This trial aimed to assess the behavioral efficacy of a highly
tailored digital intervention to support medication adherence in
patients with either or both hypertension and type 2 diabetes,
and its feasibility to support medication-related clinical
outcomes. We also examined mechanisms of action. Recruitment
and attrition rate and intervention fidelity, engagement, and
satisfaction were also reported.
Primary outcomes were the efficacy of the intervention to
support medication adherence and the feasibility of its clinical
effectiveness at a 3-month follow-up (T2). Secondary outcomes
included the mechanisms by which the intervention supported
medication adherence, as well as intervention engagement and
satisfaction.
Efficacy was measured using 2 self-reported items of adherence
(ie, days of adherence during the past week and percentage of
adherence during the past month) at T2, and repeat prescription
claims during the last 2 intervention months before T2. A
subsample of patients (n=9 intervention and n=2 control group)
were randomly selected and invited to use a Medication Event
Monitoring System caps for a duration of 7 consecutive days
after T2. Medication Event Monitoring System is an electronic
pill-bottle cap that registers the date and time of bottle opening
[16]. Patients were provided with information about how to use
the Medication Event Monitoring System and the number and
specific medications to include in the container during follow-up
consultations (see Multimedia Appendix 1). Practice records
raw data (ie, dates of prescription claims) were extracted by a
member of the practice staff from medical records and
Medication Event Monitoring System data were extracted by a
member of the research team; both nursing and research team
staff were blinded to group allocation.
Clinical outcomes were measured at T2 by nurses blinded to
group allocation during practice visits. Blood pressure was
measured in patients prescribed antihypertensive medications
and hemoglobin A1c from those prescribed glucose-lowering
medications. Blood pressure was measured 3 times with
1-minute intervals using calibrated blood pressure digital
monitor devices (eg, Omron). The last 2 readings were included
in the analysis. Blood samples were anonymized and sent to
the Addenbrookes Hospital Pathology laboratory for analysis
of hemoglobin A1c.
Quality of life was measured using the 5-level EQ-5D [17].
Medication Adherence Rating Scale [18] was used to measure
intentional nonadherence (4-items) and nonintentional
nonadherence (1-item). Feasibility was assessed by the
recruitment and attrition rate (percentage of people who
responded to the invitation and those randomized and the
percentage of people who attended consultations at follow up).
Intervention fidelity was measured by calculating the proportion
of messages received out of those messages scheduled per
patient, for the duration of the 12 weeks intervention.
Intervention engagement was calculated using the median
number of days patients interacted with the intervention during
the 12-week intervention period. Data were captured objectively
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by digital log files and extracted by a member of the research
team.
Sample Size
The sample was selected to obtain evidence about the feasibility
to implement a cost-effectiveness trial in primary care. It aimed
to provide evidence about the potential effectiveness of the
intervention, and the values needed to estimate clinically
meaningful outcomes (eg, mean and CIs for systolic blood
pressure and hemoglobin A1c). We included more participants
in the intervention group, to obtain more information about the
mechanisms by which the intervention supported medication
adherence, and about the intervention engagement and
satisfaction.
Randomization and Blinding
Block randomization (4 blocks, each of size of 25) was
conducted to ensure random group allocation. The random
sequence was generated by a centralized Web-based service
[19] and was stratified in 2 important confounders: treatment
adherence, as measured by the Medication Adherence Rating
Scale, and burden of pills. Medication Adherence Rating Scale
threshold of 24 was selected to indicate low (<24) or high (≥24)
adherence. A burden of pills ratio of 10:6 (10 tablets: 6 different
health conditions) was selected to indicate low (<10:6) or high
(≥10:6) burden of pills; and the ratio was based on our pilot
studies [12].
Data to calculate the burden of pills ratio were extracted from
medical records, and Medication Adherence Rating Scale was
self-reported. Both measures were entered into the
randomization webpage by a member of the research team, after
the completion of baseline consultations.
Health care providers were blinded to group allocation during
baseline consultations. Participants were partly blinded during
the baseline consultations as the purpose of the study was
explained to them (trial videos in Multimedia Appendix 1).
Data Analysis
The analysis was performed based on complete cases at
follow-up, excluding missing data. That is, only participants
who completed the outcome measures at follow-up were
included in the analysis. Histograms were used to explore
continuous variables’distribution, and the Levene test was used
to assess the assumption of equality of variance between groups.
A t-test was used to investigate the differences between
independent groups, and when its assumptions were not met, a
nonparametric Mann-Whitney test for independent samples was
conducted. Descriptive statistics (eg, means, SD, and
percentages) was used for comparisons between groups, and
for describing fidelity, engagement, and satisfaction with the
intervention. A subgroup analysis was performed to explore
differences in outcomes due to missing data: we compared if
there were statistically significant differences between
responders and nonresponders at each of the baseline and
follow-up outcome measures. Subgroup analyses were
performed on the total sample size. Multivariable regression
analysis was performed to explore the mechanisms by which
the intervention supported behavior change and control of
medication-related clinical outcomes. The analysis was
conducted in December 2019 using STATA.
Ethical Consideration
The study protocol was approved by the Ethics Committee of
East of England, Essex Research Ethics Committee (REC
Reference number 17/EE/0203) and Health Research Authority.
Written informed consent was obtained from all study
participants.
Results
Recruitment
A total of 4468 eligible patients were invited to the study. From
those, 256 expressed interest to participate (a 5.7% response to
the invitation), 140 were invited and attended consultations,
and 135 were deemed eligible and randomized to the
intervention (n=79) or control (n=56) group.
Randomization
The groups were very similar on baseline variables used for
minimization and for most other variables. The majority
(122/135, 90.3%) of patients were above 50 years of age (Table
1). Intervention group patients self-reported taking more pills
per day compared with usual care group patients. This variable
was not accounted for minimization, because an objective
measure of burden of pills was selected (eg, burden of pills ratio
extracted from medical records) instead of self-reports.
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Table 1. Patients characteristics at baseline.
P valueUsual care group (n=56)Intervention group (n=79)Variablesa
N/AbIndex of multiple deprivation, n (%)
6 (10.7)9 (11.4)20-30(most deprived)
31 (55.3)46 (58.3)30-40
0 (0)0 (0)40-50
4 (7.2)6 (7.6)50-60
8 (14.3)6 (7.6)60-70
7 (12.5)12 (15.1)70-80 (least deprived)
.37Age (years), n (%)
1 (1.8)0 (0)18-29
0 (0)4 (5.1)30-39
3 (5.4)5 (6.3)40-49
13 (23.2)15 (19)50-59
15 (26.8)27 (34.2)60-69
20 (35.7)26 (32.9)70-79
4 (7.1)2 (2.5)80+
.90Gender, n (%)
33 (59)40 (50.7)Male
23 (41)39 (49.3)Female
.47Employment, n (%)
10 (17.8)22 (27.8)Full-time
3 (5.4)12 (15.2)Part-time
1 (1.8)1 (1.2)Unemployed
7 (12.5)3 (3.8)Unable to work due to disease
35 (62.5)41 (52)Retired
.035.95 (5.14)8.13 (6.21)Number of pills prescribed to take per day, self-reported, mean (SD)
.064.57 (3.52)5.74 (3.67)Number of different pills prescribed to take per day, self-reported,
mean (SD)
N/AHealth condition, n (%)
38 (67.9)42 (53.2)Hypertension
16 (28.6)32 (40.5)Type 2 diabetes
2 (3.5)5 (6.3)Comorbidities of hypertension, type 2 diabetes, and cholesterol
Medication adherence, mean (SD)
.736.38 (1.29)6.46 (1.23)Number of days of adherence, last week
.4993.98 (33.32)91.19 (13.11)Percentage of adherence, last month
.3023.25 (2.32)22.78 (2.81)Medication Adherence Rating Scale
.640.95 (0.26)0.97 (0.20)Repeat prescription
Quality of life, mean (SD)
.861.74 (0.75)1.71 (0.76)EQ-5Dc, 5-items
.7447.83 (21.56)76.01 (19.68)EQ-5D, total health
aData are reported as means (SD) or number (percentage). Health condition: main comorbidities were extracted from prescription data. Index of Multiple
Deprivation was calculated based on general practice postcode; 10: low Index of Multiple Deprivation to 100: high Index of Multiple Deprivation.
Repeat prescription was defined and calculated: supply of medication claimed by the patients, excluding the next prescription day the medication was
claimed, and divided by the number of days of assessment period. Assessment period at baseline refers to the supply claimed by each patient before the
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start of the study (ie, consent process). Assessment period at follow-up refers to the last 2 months of the study. Ratio was calculated per patient due to
different denominators (eg, supply prescribed to be issued every 28 or 56 days). The overall adherence value was calculated by averaging each patient’s
ratio and dividing by the total number of patients.
bN/A: not applicable.
cEQ-5D-5L: descriptive system of health-related quality of life states consisting of five dimension (mobility, self-care, usual activities, pain/discomfort,
anxiety/depression) each of which can take one of five responses. The response record five levels of severity (no problems/slight problems/moderate
problems/ severe problems/ extreme problems) within a particular EQ-5D dimension.
Attrition Rate
At 3 months follow-up, 88% (119/135) of participants completed
the self-reported questionnaires and 85% (115/135) completed
practice visits and provided clinical outcomes. Repeat
prescription data were obtained for 87% (117/135) of the
recruited patients (Figure 1).
Figure 1. Trial CONSORT patients flow diagram.
Intervention Retention Rate
Of those randomized to the intervention group, 97% (77/79)
initiated the intervention: intervention uptake was defined by
the number of participants who responded to the intervention
messages during the first week of the intervention. Reported
reasons for not initiating the intervention after group allocation
was hospitalization. Intervention drop out was 2.5%, defined
as the number of participants requesting to stop the intervention;
and all drop out was captured during the first 4 weeks of the
intervention.
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Outcomes
The analysis found statistically significant difference in the
repeat prescription adherence (t116=2.27; P=.02; mean 0.99 [SD
0.11] for the intervention group vs 0.92 [SD 0.21] for the control
group), days of adherence (t112=2.37; P=.02; mean 6.85 [SD
0.47] vs 6.36 [SD 1.59]), Medication Event Monitoring System
(t10=4.04; P<.001; mean 6.05 [SD 2.29] vs 3.5 [SD 4.94]), and
percentage of adherence (t112=1.69; P=.05; mean 96.64 [SD
5.60] vs 91.89 [SD 18.60]) between groups, suggesting
improvements in the intervention group. Nonstatistically
significant differences in Medication Adherence Rating Scale
(t104=−0.24; P=.98; mean 23.66 [SD 1.99] vs 23.67 [SD 2.33])
between groups were found (Table 2).
Systolic blood pressure was lower (mean difference −0.6 mmHg,
95% CI −7.423 to 6.301) in the intervention group (137.8
mmHg) compared with the usual care group (138.4 mmHg).
Similarly, hemoglobin A1c was lower (a mean difference of
−4.53 mmol/l, 95% CI −13.099 to 4.710) in the intervention
group (57.2 mmol/l) in comparison to the usual care group (61.7
mmol/l), but for both of these clinical outcomes, this study was
not intended to be powered to detect significant between-group
differences. No statistically significant differences were found
in quality of life between groups (t112=0.524; P=.60; 2-tailed).
Subgroup analysis found no differences between the respondents
and the nonrespondents of each of the above-mentioned
outcomes.
Table 2. Difference between intervention and usual care group in medication adherence at 3 months follow-up.
95% CIMean differenceP value (2-tailed)Test statistic (df)Usual care groupIntervention groupOutcomea
Medication adherence
0.08 to 0.870.49.022.37 (112)6.36 (1.59)6.85 (0.47)Days adherence
−0.29 to 9.524.74.051.7 (112)91.89 (18.59)96.64 (5.60)Percentage adherence
0.00 to 0.120.07.022.27 (116)0.92 (0.21)0.99 (0.11)Repeat prescription
aFigures per complete case analysis. Data are reported as means (SD) and are not adjusted for any baseline characteristics. The numbers present the
difference between the intervention and the comparator group in outcomes at 3 months follow-up. Positive numbers present outcomes that were larger
among the intervention group than the comparator group, and negative numbers present outcomes that were smaller among the intervention group than
the comparator group.
Intervention Mechanism of Action
Multivariable regression analysis found that between-group
differences in days of medication adherence was explained by
changes in intentional and nonintentional nonadherence for the
intervention group (beta.=074, SE=0.464; P=.04), but not for
the control group (beta=.00, SE=1.35; P=.37); suggesting that
changes in intentional and nonintentional nonadherence
explained the improvements in medication adherence for the
intervention group.
Further multivariable regression analysis revealed that better
control of clinical outcomes (blood pressure <140/90mmHg or
hemoglobin A1c <42mmol/mol) was predicted by more days of
medication adherence and positive beliefs about taking
medication for the intervention group (beta=3.57, P=.03), but
not for the control group (beta=.795, P=.46).
Intervention Fidelity, Engagement, and Satisfaction
Intervention fidelity was 100% for the total duration of the
intervention, suggesting that all messages were delivered as
scheduled. Most (56/77, 73%) intervention group patients
selected to receive 1 intervention message per day and some
(21/77, 27%) selected to receive 2 messages per day. The
majority of patients selected to receive intervention messages
around the time they used to take their medications.
Total intervention engagement was 12 days, suggesting that
patients interacted with the digital intervention and potentially
engaged with the medication adherence intervention.
The majority of the participants found the intervention easy to
use (51/70, 73%), liked the automated voice delivering the voice
messages (44/70, 62.5%), the content of the messages (50/70,
71.5%), and the availability to call and ask questions when
needed (36/70, 51.6%). Overall, patients were satisfied with the
experience with the intervention (53/70, 76%), and they would
recommend it to other people who take medications for a
long-term health condition (46/70, 65%; Multimedia Appendix
2).
Discussion
Principal Findings
Among those patients with either or both high blood pressure
and high glucose levels recruited from primary care practices,
patients who used the digital intervention improved their
adherence to medication at 3 months by an average of 2 days
(intervention effect size Cohen d=0.42), compared with those
continuing with their usual care only. Taking into consideration
that adherence declines during the first month following usual
care consultations [20], our trial suggests that the intervention
can support treatment adherence to nonadherent patient.
The attrition rate was low, and the end of intervention clinical
outcomes found that the intervention group patients had lower
blood pressure and lower glucose levels, compared with those
allocated in the control group. Although the study was not
powered to assess effectiveness in clinical outcomes, considering
the impact of medication nonadherence on uncontrolled blood
pressure [21] and uncontrolled hemoglobin A1c [22,23], these
results provide us with confidence that the intervention is
feasible and could potentially be an effective adjunct to primary
care consultation.
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The intervention effectively improved medication adherence
by modifying patients' intentional and nonintentional
nonadherence, which proves the importance of the highly
tailored intervention to support health behavior change. This
result proves that this highly tailored intervention can effectively
support the processes of behavioral change and in turn the health
behavioral outcomes.
It was also found that patients interacted with the digital
intervention for 12 days, which provides us with confidence
that patients engaged with the medication adherence intervention
[24], a prerequisite to achieve behavior change and clinically
meaningful outcomes at least in the short term.
Strengths and Limitations
This trial provides evidence about the efficacy of the
intervention to improve medication adherence based on
self-reports, which might over estimate adherence levels.
Nevertheless, the proxy measure of adherence, that is, the repeat
prescription claims, was statistically significant, which provides
us with confidence about the efficacy of the intervention;
although both these measures do not directly reflect
medication-taking behavior.
Another strength of the study is the recruitment of patients from
a range of primary care practices, most in highly deprived areas.
Considering the challenges with recruitment in a primary care
setting [25], the recruitment rate provided us with confidence
that the interventions can be scaled up to a wider range of
practices and reach patients of different socioeconomic
backgrounds.
A limitation of this study is that we could not reliably identify
the patterns of nonadherent behavior (eg, frequency and
sequence of nonadherent behavior) when patients were enrolled
in the study. Similarly, we could not reliably identify the
frequency of changes in prescribed medications, as well as the
reasons for these changes (eg, therapeutic thresholds reported
by patients or clinicians) [26]. Nevertheless, we decided to enroll
all patients, regardless of the patterns or reasons of past
nonadherence, to obtain more information about the intervention
engagement and mechanism of action.
Possible Mechanisms and Implications for Clinicians
or Policymakers
The results of this study suggest that the intervention was
effective at improving medication adherence by supporting
intentional and nonintentional nonadherence, had good
engagement and satisfaction, and low attrition rate. In view of
the demographics of the participants, who had more experience
with and possibly expectation of patient-clinician interactions,
and the recruitment setting of the study [25], these findings
prove that the digital intervention is a feasible and acceptable
adjunct to primary care consultation.
The baseline face-to-face consultation lasted on average 30 min
and involved the completion of study procedures and signposting
patients to the digital intervention, in addition to usual care (eg,
addressing patients' concerns and side effects). From those
patients allocated to the digital intervention, only 1% requested
additional human support regarding the use of this technology,
and requests involved changes to the time of the message
delivery, or the dose or the name of the medication when a
change in the prescribed tablet was recommended by their health
care providers. Moreover, the low attrition rate suggests that
the intervention is highly acceptable as an adjunct to usual care.
Given that the cost to deliver the digital intervention is very
little (monthly cost of £0.029 per patient), and there were no
adverse events or additional consultations recorded during the
3 months, it is likely that the intervention is inexpensive for the
primary care.
Future Directions
Improved medication adherence has been associated with
decrease in all-cause mortality and morbidity, and digital
interventions can be a solution to rapidly evolve the provision
of health care [10]. Future research of larger sample sizes and
objective outcome measures for medication adherence (eg, urine
analysis for detection of antihypertensive medication) is needed
to provide evidence about the effectiveness and
cost-effectiveness of the intervention to support treatment
adherence and clinical outcomes.
Conclusions
This is the first trial that has been conducted in the primary care
setting in the United Kingdom. The finding of this feasibility
trial suggests that the intervention is a feasible adjunct to
primary care consultations and effective in improving
medication adherence and process of care to patients
nonadherent to either or both antihypertensive and antiglycaemic
medications. The intervention is scalable and low cost. More
research is needed to evaluate its effectiveness and cost
effectiveness.
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